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Behcet's disease is a multi-systemic and chronic inﬂammatory vasculitis of unknown etiology charac-
terized by recurrent oral and genital ulcers, uveitis, arthritis, arterial aneurysms, venous thrombosis, skin
lesions and GIS lesions. Although pulmonary artery aneurysms are rare, it is a critical condition due to
high risk of rupture. Venous involvement of Behcet's disease primarily occurs in the lower extremities. In
the presence of deep vein thrombosis(DVT) and pulmonary embolism, the mainstay of treatment in
Behcet's disease is immunosuppressant therapy. Anticoagulants can be used only after initiation of
immunosuppressant therapy and suppression of the disease. Anticoagulant therapy alone may lead to
fatal hemoptysis. We report the case of a 24 year-old patient who presented to the emergency service
with complaints of shortness of breath, general condition disorder and hemoptyhis while using warfarin
for DVT and whose thoracic CT angiography showed pulmonary embolism and pulmonary artery
aneurysm and diagnosed with Behcet's disease.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Behcet's disease is a multisytemic and vasculitic disease of un-
known etiology, which was described by Hulusi Behçet in 1937.
Although it is reported from all over the world, Behcet's disease is
more prevalent in Mediterranean countries like Turkey, Greece and
Israel [1]. The main features of pulmonary involvement in Behcet's
disease include arterial and venous thrombosis, pulmonary artery
aneurysms, pulmonary infarction, recurrent pneumonia and pleu-
risy [2]. Life threatening pulmonary artery aneurysms may show
regression with medical treatment [3]. Vascular involvement in
Behcet's disease occurs in more than 40% of the cases, and it most
common affects the lower extremities [4]. While these in-
volvements are seen concomitantly, the treatment remains
controversial.
A patient who was on warfarin for deep vein thrombosis (DVT)
was presented for hemoptysis. His thoracic CT angiography showed
pulmanory embolism accompanied by pulmonary artery aneurysm.
He was clinically and radiologically diagnosed with Behcet'so.com (A.C. Güngen),
r@yahoo.com (Y. Aydemir),
Ltd. This is an open access article udisease. We wanted to discuss concomitance of pulmonary artery
aneurysms and pulmonary embolism and challenges in treatment
due to presence of hemoptysis and embolism together by pre-
senting our case.2. Case presentation
A 24 year-old male patient was presented to the emergency
service with a complaint of hemoptysis. His body temperature
was 36.9 C; pulse rate was 76/min; respiratory rate was 14/min;
arterial blood pressure was 110/60 mmHg; and he had normal
breath sounds. The chest x-ray showed that peripheral consoli-
dation in the right middle zone (Fig. 1). The investigations
showed WBC 7600/ml, Hgb 12.8 gr/dl, and platelet count
224.000, and his biochemical ﬁndings were normal. D-dimer
level was 2260, sedimentation was 48 mm/h and INR was 3.2.
Rheumatoid factor was 46 IU/ml, and HLA B51 antigen was not
present. Anti-nuclear antibodies, anti-double stranded DNA,
cytoplasmic, and perinuclear types of anti-neutrophil cyto-
plasmic antibodies were negative. Pathergy skin test was not
performed due to immediate initiation of steroid treatment. The
patient received a diagnosis of DVT 2 months ago in an external
center, and hıs treatment was initiated with warfarin. Thoracic
CT angiography showed pulmonary embolism and pulmonarynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chest X-ray showed inﬁltration in right middle zone, and right sinus was closed.
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right-sided cardiac structures were larger than normal, and
pulmonary artery pressure was 44 mmHg. His medical history of
genital and oral ulcers, young age, presence of DVT and pulmo-
nary artery aneursym clinically and radiologically suggested
Behcet's disease. Without any prior diagnosis of Behcet's disease,
the patient was admitted to the Chest Diseases Clinic. Treatment
with coumadin was ended due to hemoptysis. He was initiated
on treatment with prednisolone 1000 mg for three consecutive
days. His CRP level decreased from 25 mg/L to 4 mg/L, and after
development of hemopthysis, his therapy was switched to
methylprednisolone 40 mg IV b.i.d. and azathioprine tablet
50 mg PO t.i.d. The lower extremity venous Doppler examination
was repeated on the seventh day of his therapy due to complaint
of pain, swelling and heat in his leg, and after demonstration of
minimal recanalization of the left common femoral and popliteal
vein with total thrombus, patient was started to be given enox-
aparin Na 0.4 ml SC b.i.d. Hemopthysis did not recur after
treatment with enoxaparine sodium. During control tests, D-
dimer levels was reduced to 220, and pulmonary artery pressure
was reduced to 28 mmHg on echocardiography. Uveitis was not
detected during eye examination.3. Discussion
The case of this patient showed us that young and male pa-
tients diagnosed with DVT should be examined for Behcet's
disease before initiation of an anticoagulant therapy. It is to be
considered that to ınıtıate anticoagulant therapy before the
exclusion of Behcet's Disease may lead to fatal hemoptysis in the
presence of pulmonary artery aneursym. In Behcet's Disease,
pulmonary embolism is not associated with DVT. Pulmonary
embolism is associated with endothelial damage. The maintasy
treatment is immunosuppresive therapy in the presence of pul-
monary embolism.
Behcet's disease is a systemic vasculitis with vessel involvement
of any type and size. Vessel involvement is the leading cause of
mortality in Behcet's disease. The involvement can be both in thearterial and venous systems, however venous system involvement
is more common. The prevalence of vessel involvement in Behcet's
disease varies by country and region. The series of cases with more
vessel involvement were reported from Morocco [5] (62.34%),
while series of cases with less vessel involvement were from Japan
[6] (7.7%) and Turkey [7] (8%). A common point of these studies was
that vessel involvement of Behcet's disease was more common in
males and they had a slower course in comparison to females.
Moreover, pathergy positivity, superﬁcial thrombophlebitis, ery-
thema nodosum, neurological involvement and GIS involvement
were signiﬁcantly more common in patients with vesssel involve-
ment, and those with eye involvement had less vessel involvement.
The most common site is venous thrombosis which mainly occurs
in the lower extremities. They occur in 25e30% of the patients.
DVTs is common in the ﬁrst years after onset of the disease. DVT has
the potential to be more severe and bilaterally in Behcet's disease
[8,9].
Although large vessel involvement varies by series, it has a
prevalence of 5e10%. In Behcet's disease arterial system is
involved around 5%, and it occurs in later years compared to the
venous system involvement, but arterial manifestations are
among the leading major causes of morbidity and mortality.
Pulmonary artery aneurisym is the most common form of pul-
monary involvement in patients with Behcet's disease. A litera-
ture review of many cases showed a pulmonary artery
involvement of 3.9%. Pulmonary artery aneurysms may be
complicated with rupture, resulting in pulmonary hemorrhage
and hemoptysis leading to death [10]. The objective of treatment
in Behcet's disease is the suppression of inﬂammation particu-
larly in early years, and prevention of complications. An effective
treatment is critical before irreversible organ damage. Use of
systemic high dose steroids are common in active large vessel
involvement. Cyclophosphamide therapy with an oral dose of
2e2.5 mg/kg/day or as weekly or monthly intravenous pulses of
500e100 mg is implemented in patients with large vessel
involvement [11,12]. If thrombophlebitis develops during the
course of Behcet's disease, role of heparin or oral anticoagulants
is controversial. In a study comparing immunosupressive therapy
and anticoagulant therapy in Behcet's disease with venous
thrombosis, the patients were divided into three groups ac-
cording to the treatment they received; immunosupressive
therapy plus anticoagulation, immunosuppression alone, and
anticoagulation alone. Although venous thrombosis recurrence
was less common in the group receiving immunosupressive
therapy plus anticoagulation, there was no statistically signiﬁ-
cant difference between the group receiving immunosupressive
therapy alone [13]. Another approach is to screen each Behcet'
disease patient with thrombosis for genetic markers (factor V
Leiden, prothrombin gene, protein C, protein S, antithrombin and
anticardiolipin antibody). Some authors believe that immuno-
supressive therapy is to be combined with anticoagulant therapy
in Behcet's disease patients with presence of a marker facilitating
thrombosis [14]. If warfarin is used as an anticoagulant, possible
drug-drug interactions should be taken into consideration. In
patients with Behcet' disease, azathioprine used for immunosu-
pressive therapy may inhibit the anticoagulant effect of warfarin,
which may result in development of resistance to warfarin [15].
Therefore, warfarin dose may need to be increased. As seen in
our patient, if thrombophlebitis is accompanied by pulmonary
artery aneurysm, hemoptysis may develop as a result of erosion
of the pulmonary artery aneurysm into the lumen of a bronchus.
Again, as seen in our patient, concomitant anticoagulant therapy
that is initiated in Behcet's disease with undiagnosed pulmonary
embolism may lead to fatal outcomes since it will contribute to
aneurysmal hemorrhage. Studies have shown that despite
Fig. 2. Thorax CT imaging, before and after treatment. A: Images during the diagnosis B: Images after the treatment.
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pulmonary artery aneurysms [16].
In conclusion, involvement of vessels in Behcet's disease is a
subgroup of conditions which is more common in males with a
high mortality. Endothelial dysfunction is the most important fac-
tor with an evidence of a role in the etiopathology of vessel
involvement. Immunosupressive therapy (treatment with cyclo-
phosphamide and corticosteroids) should be preferred for treat-
ment of large vessel involvement. Anticoagulant therapy may be
beneﬁcial in Behçet's disease patients particularly with thrombosisif DVT persists after initiation of immunosuppressive therapy or
provided that presence of aneurysm is excluded.
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